

Corporate Satellite Symposium

Luncheon Symposium: Supported by Amgen Oncology



Saturday, 3 July 2010

13:15 - 14:45

Level 1, Rooms 116 - 117

Challenges in the management of mCRC: Treatment options under scrutiny

Chair: *Arnaud Roth*

Opening remarks
Arnaud Roth
Geneva, Switzerland

Key statistical issues in the correct interpretation of data
Richard Kay
Bakewell, United Kingdom

Case discussions*: Treatment options in 2010 and beyond
Moderator: *Arnaud Roth*
Geneva, Switzerland

Panel: *Thierry André*, Paris, France
Dirk Arnold, Halle, Germany
Stefano Cascinu, Ancona, Italy
Richard Kay, Bakewell, United Kingdom
Bernard Nordlinger, Paris, France
Ramón Salazar, Barcelona, Spain

Closing remarks
Arnaud Roth
Geneva, Switzerland

*Cases for discussion will include patients from 1st- and 2nd-line mCRC settings with KRAS wild type, KRAS mutant or BRAF mutant tumors.